Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
Enochian BioSciences Inc. (NASDAQ: ENOB) has announced its full compliance with NASDAQ listing requirements after filing essential reports. The Annual Report on Form 10-K was submitted on February 27, 2023, followed by Quarterly Reports on Forms 10-Q for the respective quarters on March 7 and March 9, 2023. Lead Independent Board Member, Gregg Alton, expressed satisfaction with the Company’s compliance status. CEO Dr. Mark Dybul emphasized the importance of this milestone and the company's strong scientific foundation, mentioning plans to advance novel technology targeting solid tumors, potentially progressing to clinical phases by early 2024.
- Achieved full compliance with NASDAQ filing requirements.
- Successful filing of 10-K and 10-Q reports on time.
- CEO indicates strong science and potential advancements in cancer treatment.
- None.
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively.
“I am very pleased that the Company is once again compliant with the NASDAQ listing requirements. We have turned another page towards a promising future,” said Gregg Alton, former long-time General Counsel and Chief Compliance Officer and, later, Interim CEO of Gilead Sciences, and Lead Independent Board Member of Enochian BioSciences.
Dr. Mark Dybul, CEO of the Company, said, “Returning to full compliance is a significant accomplishment. Despite challenges, the science remains strong and encouraging. I look forward to the Company advancing its novel technology to possibly treat several solid tumors with relatively poor life expectancy from pre-clinical to clinical phase potentially by early 2024.”
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Source: Enochian Biosciences Inc.
FAQ
What recent compliance achievement did Enochian BioSciences Inc. announce?
What reports were filed by Enochian BioSciences in 2023?
What does the CEO of Enochian BioSciences say about their technology?
Who commented on Enochian BioSciences' compliance with NASDAQ?
